Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Rituximab 32fludarabine phosphate 28Cyclophosphamide 26Filgrastim 13Peripheral Blood Stem Cell Transplantation 12ibrutinib 11Bortezomib 11Lenalidomide 10alvocidib 9Cyclosporine 9tanespimycin 8Biopsy 8fludarabine 7Vincristine 7Radiotherapy 7Etoposide 7Specimen Handling 6romidepsin 5bryostatin 1 5apolizumab 5Vorinostat 5Methotrexate 5Ifosfamide 5Cytarabine 5CT-P10 5Busulfan 5temsirolimus 4laromustine 4aldesleukin 4Thalidomide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Lymphocytic, Chronic, B-Cell × ON 01910 × Clear all
NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡